For people with multiple sclerosis (PwMS), within-person reductions in daytime activity patterns precede clinical disability worsening, according to a study published online March 4 in Neurology.

Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue ...

A predictive tool considering disease duration, age at disease onset, age, and Expanded Disability Status Scale score estimated patients’ risk of transition to secondary progressive multiple sclerosis ...

Clinical outcome measurement in multiple sclerosis encompasses a spectrum of tools and approaches designed to quantify disease activity, functional impairment and quality of life. Traditional ...

Panelists discuss how disability progression can be measured through practical clinical tools like patient-reported outcomes, timed walking tests, and dexterity assessments rather than relying solely ...

Once multiple sclerosis (MS) is diagnosed (see presentation), periodic assessment of disease severity is important both for tracking disease progression (and establishing prognosis) and for monitoring ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).